Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2014

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #658

    Hehe den anonyme smed et bundt aktier ud og ryddede ned til 228 - C
    arnegie kom så på banen

    1 Reply Last reply
    0
    • G Offline
      G Offline
      gdn55
      wrote on sidst redigeret af
      #659

      Hvad mon der sker efter luk.

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #660

        Det rykker noget i dag...

        1 Reply Last reply
        0
        • investor1989I Offline
          investor1989I Offline
          investor1989
          wrote on sidst redigeret af
          #661

          +6% er længe siden vi sidst har set

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #662

            +4% på c20 indeks ?

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #663

              Er væksten kommet til Europa ?

              1 Reply Last reply
              0
              • J Offline
                J Offline
                JKY_VH
                wrote on sidst redigeret af
                #664

                Det er bare mig der er kommet hjem fra ferie:-)

                1 Reply Last reply
                0
                • C Offline
                  C Offline
                  cpi
                  wrote on sidst redigeret af
                  #665

                  tja, det luk i us bliver vi vist ikke klogere af, hælder mest til, vi skal ned på mandag, måske en 3-5 kr.

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #666

                    Jeg synes den er helt umulig at spå om...

                    1 Reply Last reply
                    0
                    • investor1989I Offline
                      investor1989I Offline
                      investor1989
                      wrote on sidst redigeret af
                      #667

                      Revlimid det 10 dyreste lægemiddel pr. patient i verden: http://www.fiercepharma.com/special-reports/top-10-most-expensive-drugs-2013 Alexions lægemiddel klart dyrest

                      1 Reply Last reply
                      0
                      • BudweisB Offline
                        BudweisB Offline
                        Budweis
                        wrote on sidst redigeret af
                        #668

                        Dette interview William R. Strohl (VP hos Janssen) er ret interessant - http://www.bizjournals.com/philadelphia/blog/health-care/2014/08/why-the-next-big-biologic-may-be-found-by-montco.h
                        tml

                        1 Reply Last reply
                        0
                        • BudweisB Offline
                          BudweisB Offline
                          Budweis
                          wrote on sidst redigeret af
                          #669

                          Just a moment...

                          favicon

                          (www.bizjournals.com)

                          1 Reply Last reply
                          0
                          • BudweisB Offline
                            BudweisB Offline
                            Budweis
                            wrote on sidst redigeret af
                            #670

                            Strohl said one of the difficulties in developing bispecific antibodies is overcoming manufacturing hurdles. “Most can’t be manufactured,” he said. “I have to say we were a little frustrated that we couldn’t develop, internally, a technology that could be trusted to be manufacturable.”

                            Genmab’s technology proved to be the most promising solution. “We now have 20 bispecific licenses with them,” Strohl said.

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #671

                              Tak for info Budweis.

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #672

                                Ja meget opmuntrende læsning. Kunne Janssen så ikke lige også nappe en aftale på hexabody.

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #673

                                  Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT’s three OmniAb™ platforms, OmniRat®, OmniMouse® and OmniFlic™

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #674

                                    Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for creation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with three transgenic animal platforms

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #675

                                      OMT has granted unlimited platform access to Genmab, Genentech, Janssen, Merck KGaA, Pfizer, Roche, Symphogen

                                      1 Reply Last reply
                                      0
                                      • investor1989I Offline
                                        investor1989I Offline
                                        investor1989
                                        wrote on sidst redigeret af
                                        #676

                                        Genmab vil have adgang til flere antistoffer som de kan kombinere i duobody

                                        1 Reply Last reply
                                        0
                                        • celsiusC Offline
                                          celsiusC Offline
                                          celsius
                                          wrote on sidst redigeret af
                                          #677

                                          Det Europæiske Lægemiddelagentur har godkendt lægemidlet Imbruvica (ibrutinib) fra Janssen og partneren Pharmacyclics til to indikationer inden for behandling af blodkræft. Markedet skærpes nu for alvor for Genmab. Er der nogen der ønsker at kommentere på det ? I artiklen står der at Imbrutinib skulle være i fase 3 kombi med Arzerra .. har det sin rigtighed ?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger